Variable fragments of heavy chain antibodies (VHHs): A new magic bullet molecule of medicine?

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 348-358

  Smolarek, Dorota ^a,b,c,d   Bertrand, Olivier ^b,c,d   Czerwinski, Marcin ^a,e  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b hôpital Robert Debré et Institut national de la transfusion sanguine   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e OPOLE UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Heavy chain antibodies; Nanobody; VHH

Indexed keywords

EID: 84867927669     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1000334     Document Type: Review

References (90)

1. Abderrazek R. B., Hmila I., Vincke C., Benlasfar Z., Pellis M., Dabbek H., Saerens D., El Ayeb M., Muyldermans S., Bouhaouala-Zahar B.: Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem. J., 2009;424:263-272
2. Abulrob A., Sprong H., Van Bergen en Henegouwen P., Stanimirovic D.: The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem., 2005;95:1201-1214
3. Ahmadvand D., Rasaee M. J., Rahbarizadeh F., Kontermann R. E., Sheikholislami F.: Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol., 2009;46:1814-1823
4. Baral T. N., Magez S., Stijlemans B., Conrath K., Vanhollebeke B., Pays E., Muyldermans S., De Baetselier P.: Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med., 2006;12:580-584
5. Behar G., Sibéril S., Groulet A., Chames P., Pugniere M., Boix C., Sautes-Fridman C., Teillaud J. L., Baty D.: Isolation and characterization of anti-FcγRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng. Des. Sel., 2008;21:1-10
6. Chopra A.: [99mTc]Epidermal growth factor receptor-specific nanobody. Molecular Imaging and Contrast Agent Database, 2008
7. Conrath K., Pereira A. S., Martins. C. E., Timóteo C. G., Tavares P., Spinelli S., Kinne J., Flaudrops C., Cambillau C., Muyldermans S., Moura I., Moura J. J., Tegoni M., Desmyter A.: Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase. Protein Sci., 2009;18:619-628
8. Conrath K. E., Lauwereys M., Galleni M., Matagne A., Frere J. M., Kinne J., Wyns L., Muyldermans S.: β-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother., 2001;45:2807-2812
9. Conway J. O., Sherwood L. J., Collazo M. T., Garza J. A., Hayhurst A.: Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One, 2010;5:e8818
10. Coppieters K., Dreier T., Silence K., de Haard H., Lauwereys M., Casteels P., Beirnaert E., Jonckheere H., Van de Wiele C., Staelens L., Hostens J., Revets H., Remaut E., Elewaut D., Rottiers P.: Formatted anti-tumor necrosis factor a VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum., 2006;54:1856-1866
11. Cortez-Retamozo V., Backmann N., Senter P. D., Wernery U., De Baetselier P., Muyldermans S., Revets H.: Efficient cancer therapy with a nanobody-based conjugate. Cancer Res., 2004;64:2853-2857
12. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., De Baetselier P., Revets H.: Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer, 2002;98:456-462
13. Czerwiński M., Krop-Wa̧torek A.: Heavy-chain antibodies of the Camelidae and their possible applications. Postȩpy Hig. Med. Dośw., 2005;59:193-202
14. De Genst E., Saerens D., Muyldermans S., Conrath K.: Antibody repertoire development in camelids. Dev. Comp. Immunol., 2006;30:187-198
15. De Haard H. J., Bezemer S., Ledeboer A. M., Müller W. H., Boender P. J., Moineau S., Coppelmans M. C., Verkleij A. J., Frenken L. G., Verrips C. T.: Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J. Bacteriol., 2005;187:4531-4541
16. Deschacht N., De Groeve K., Vincke C., Raes G., De Baetselier P., Muyldermans S.: A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. J. Immunol., 2010;184:5696-5704
17. Desmyter A., Decanniere K., Muyldermans S., Wyns L.: Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem., 2001;276:26285-26290
18. Desmyter A., Spinelli S., Payan F., Lauwereys M., Wyns L., Muyldermans S., Cambillau C.: Three camelid VHH domains in complex with porcine pancreatic α-amylase. Inhibition and versatility of binding topology. J. Biol. Chem., 2002;277:23645-23650
19. Desmyter A., Transue T. R., Ghahroudi M. A., Thi M. H., Poortmans F., Hamers R., Muyldermans S., Wyns L.: Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol., 1996;3:803-811
20. Diaz M., Greenberg A. S., Flajnik M. F.: Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen-driven reactions in the absence of germinal centers. Proc. Natl. Acad. Sci. USA, 1998;95:14343-14348
21. Diaz M., Stanfield R. L., Greenberg A. S., Flajnik M. F.: Structural analysis, selection, and ontogeny of the shark new antigen receptor (IgNAR): identification of a new locus preferentially expressed in early development. Immunogenetics, 2002;54:501-512
22. Dolk E., van der Vaart M., Lutje Hulsik D., Vriend G., de Haard H., Spinelli S., Cambillau C., Frenken L., Verrips T.: Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl. Environ. Microbiol., 2005;71:442-450
23. Dong J., Thompson A. A., Fan Y., Lou J., Conrad F., Ho M., Pires-Alves M., Wilson B. A., Stevens R. C., Marks J. D.: A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic α-exosite binding region. J. Mol. Biol., 2010;397:1106-1118
24. Dudek J., Benedix J., Cappel S., Greiner M., Jalal C., Müller L., Zimmermann R.: Functions and pathologies of BiP and its interaction partners. Cell. Mol. Life Sci., 2009;66:1556-1569
25. Flajnik M. F., Deschacht N., Muyldermans S.: A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol., 2011;9:e1001120
26. Forsman A., Beirnaert E., Aasa-Chapman M. M., Hoorelbeke B., Hijazi K., Koh W., Tack V., Szynol A., Kelly C., McKnight A., Verrips T., de Haard H., Weiss R. A.: Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol., 2008;82:12069-12081
27. Frenken L. G., van der Linden R. H., Hermans P. W., Bos J. W., Ruuls R. C., de Geus B., Verrips C. T.: Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol., 2000;78:11-21
28. Gainkam L. O., Caveliers V., Devoogdt N., Vanhove C., Xavier C., Boerman O., Muyldermans S., Bossuyt A., Lahoutte T.: Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol. Imaging, 2011;6:85-92
29. Gainkam L. O., Huang L., Caveliers V., Keyaerts M., Hernot S., Vaneycken I., Vanhove C., Revets H., De Baetselier P., Lahoutte T.: Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med., 2008;49:788-795
30. Greenberg A. S., Avila D., Hughes M., Hughes A., McKinney E. C., Flajnik M. F.: A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature, 1995;374:168-173
31. Groot A. J., El Khattabi M., Sachs N., van der Groep P., van der Wall E., van Diest P. J., Sonnenberg A., Verrips C. T., Vooijs M.: Reverse proteomic antibody screening identifies anti adhesive VHH targeting VLA-3. Mol. Immunol., 2009;46:2022-2028
32. Habib I., Smolarek D., Hattab C., Gangnard S., Cochet S., Nunes de Silva S., Le Van Kim C., Colin Y., Czerwinski M., Bertrand O.: Methods for efficient, straightforward expression and purification of VHH, recombinant derivatives of heavy chain only camelid antibodies. 19th Biennial Meeting of the International Society for Molecular Recognition Tavira, Portugal, 16-19 June, 2011
33. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E. B., Bendahman N., Hamers R.: Naturally occurring antibodies devoid of light chains. Nature, 1993;363:446-448
34. Harmsen M. M., De Haard H. J.: Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol., 2007;77:13-22
35. Harmsen M. M., van Solt C. B., van Zijderveld-van Bemmel A. M., Niewold T. A., van Zijderveld F. G.: Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl. Microbiol. Biotechnol., 2006;72:544-551
36. Hendershot L., Bole D., Kearney J. F.: The role of immunoglobulin heavy chain binding protein in immunoglobulin transport. Immunology Today, 1987;8:111-114
37. Hmila I., Abdallah R. B., Saerens D., Benlasfar Z., Conrath K., Ayeb M. E., Muyldermans S., Bouhaouala-Zahar B.: VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin Aahl'. Mol. Immunol., 2008;45:3847-3856
38. Hmila I., Saerens D., Ben Abderrazek R., Vincke C., Abidi N., Benlasfar Z., Govaert J., El Ayeb M., Bouhaouala-Zahar B., Muyldermans S.: A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J., 2010;24:3479-3489
39. Huang L., Gainkam L. O., Caveliers V., Vanhove C., Keyaerts M., De Baetselier P., Bossuyt A., Revets H., Lahoutte T.: SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol., 2008;10:167-175
40. Hulstein J. J., de Groot P. G., Silence K., Veyradier A., Fijnheer R., Lenting P. J.: A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood, 2005;106:3035-3042
41. Ibañez L. I., De Filette M., Hultberg A., Verrips T., Temperton N., Weiss R. A., Vandevelde W., Schepens B., Vanlandschoot P., Saelens X.: Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J. Infect. Dis., 2011;203:1063-1072
42. Iqbal U., Trojahn U., Albaghdadi H., Zhang J., O'Connor-McCourt M., Stanimirovic D., Tomanek B., Sutherland G., Abulrob A.: Kinetic analysis of novel mono-and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br. J. Pharmacol., 2010;160:1016-1028
43. Ismaili A., Jalali-Javaran M., Rasaee M. J., Rahbarizadeh F., Forouzandeh-Moghadam M., Memari H. R.: Production and characterization of anti-(mucin MUC1) single-domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol. Appl. Biochem., 2007;47:11-19
44. Jähnichen S., Blanchetot C., Maussang D., Gonzalez-Pajuelo M., Chow K. Y., Bosch L., De Vrieze S., Serruys B., Ulrichts H., Vandevelde W., Saunders M., De Haard H. J., Schols D., Leurs R., Vanlandschoot P., Verrips T., Smit M. J.: CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. USA, 2010;107:20565-20570
45. Koh W. W., Steffensen S., Gonzalez-Pajuelo M., Hoorelbeke B., Gorlani A., Szynol A., Forsman A., Aasa-Chapman M. M., de Haard H., Verrips T., Weiss R. A.: Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1. J. Biol. Chem., 2010;285:19116-19124
46. Köhler G., Milstein C.: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975;256:495-497
47. Ladenson R. C., Crimmins D. L., Landt Y., Ladenson J. H.: Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal. Chem., 2006;78:4501-4508
48. Lafaye P., Achour I., England P., Duyckaerts C., Rougeon F.: Singledomain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol., 2009;46:695-704
49. Ledeboer A. M., Bezemer S., de Hiaard J. J., Schaffers I. M., Verrips C. T., van Vliet C., Düsterhöft E. M., Zoon P., Moineau S., Frenken L. G.: Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. J. Dairy Sci., 2002;85:1376-1382
50. Li J. W., Xia L., Su Y., Liu H., Xia X., Lu Q., Yang C., Reheman K.: Molecular imprint of enzyme active site by camel nanobodies: rapid and efficient approach to produce abzymes with alliinase activity. J. Biol. Chem., 2012;287:13713-13721
51. Maattanen P., Gehring K., Bergeron J. J., Thomas D. Y.: Protein quality control in the ER: the recognition of misfolded proteins. Semin. Cell Dev. Biol., 2010;21:500-511
52. Meddeb-Mouelhi F., Bouhaouala-Zahar B., Benlasfar Z., Hammadi M., Mejri T., Moslah M., Karoui H., Khorchani T., El Ayeb M.: Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon, 2003;42:785-791
53. Moutel S., Perez F.: Intrabodies, potent tools to unravel the function and dynamics of intracellular proteins. Med. Sci., 2009;25:1173-1176
54. Muyldermans S.: Single domain camel antibodies: current status. J. Biotechnol., 2001;74:277-302
55. Muyldermans S., Atarhouch T., Saldanha J., Barbosa J. A., Hamers R.: Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng., 1994;7:1129-1135
56. Nguyen V. K., Desmyter A., Muyldermans S.: Functional heavy-chain antibodies in Camelidae. Adv. Immunol., 2001;79:261-296
57. Nguyen V. K., Hamers R., Wyns L., Muyldermans S.: Loss of splice consensus signal is responsible for the removal of the entire C (H) 1 domain of the functional camel IGG2A heavy-chain antibodies. Mol. Immunol., 1999;36:515-524
58. Nguyen V. K., Hamers R., Wyns L., Muyldermans S.: Camel heavy-chain antibodies: diverse germline V (H) H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J., 2000;19:921-930
59. Pant N., Hultberg A., Zhao Y., Svensson L., Pan-Hammarstrom Q., Johansen K., Pouwels P. H., Ruggeri F. M., Hermans P., Frenken L., Boren T., Marcotte H., Hammarstrom L.: Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J. Infect. Dis., 2006;194:1580-1588
60. Perk K., Frei Y. F., Herz A.: Osmotic fragility of red blood cells of young and mature domestic and laboratory animals. Am. J. Vet. Res., 1964;25:1241-1248
61. Rahbarizadeh F., Ahmadvand D., Sharifzadeh Z.: Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest., 2011;40:299-338
62. Rahbarizadeh F., Rasaee M. J., Forouzandeh M., Allameh A. A.: Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol., 2006;43:426-435
63. Rajabi-Memari H., Jalali-Javaran M., Rasaee M. J., Rahbarizadeh F., Forouzandeh-Moghadam M., Esmaili A.: Expression and characterization of a recombinant single-domain monoclonal antibody against MUC1 mucin in tobacco plants. Hybridoma, 2006;25:209-215
64. Rothbauer U., Zolghadr K., Muyldermans S., Schepers A., Cardoso M. C., Leonhardt H.: A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell. Proteomics, 2008;7:282-289
65. Rothbauer U., Zolghadr K., Tillib S., Nowak D., Schermelleh L., Gahl A., Backmann N., Conrath K., Muyldermans S., Cardoso M. C., Leonhardt H.: Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods, 2006;3:887-889
66. Roux K. H., Greenberg A. S., Greene L., Strelets L., Avila D., McKinney E. C., Flajnik M. F.: Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc. Natl. Acad. Sci. USA, 1998;95:11804-11809
67. Saerens D., Pellis M., Loris R., Pardon E., Dumoulin M., Matagne A., Wyns L., Muyldermans S., Conrath K.: Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol., 2005;352:597-607
68. Serruys B., Van Houtte F., Farhoudi-Moghadam A., Leroux-Roels G., Vanlandschoot P.: Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. J. Gen. Virol., 2010;91:643-652
69. Siller-Matula J. M., Krumphuber J., Jilma B.: Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br. J. Pharmacol., 2010;159:502-517
70. Smith M. H., Ploegh H. L., Weissman J. S.: Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science, 2011;334:1086-1090
71. Smolarek D., Hattab C., Hassanzadeh-Ghassabeh G., Cochet S., Gutiérrez C., de Brevern A. G., Udomsangpetch R., Picot J., Grodecka M., Wasniowska K., Muyldermans S., Colin Y., Le Van Kim C., Czerwinski M., Bertrand O.: A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines. Cell. Mol. Life Sci., 2010;67:3371-3387
72. Spinelli S., Frenken L. G., Hermans P., Verrips T., Brown K., Tegoni M., Cambillau C.: Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry, 2000;39:1217-1222
73. Spinelli S., Tegoni M., Frenken L., van Vliet C., Cambillau C.: Lateral recognition of a dye hapten by a llama VHH domain. J. Mol. Biol., 2001, 311:123-129
74. Stijlemans B., Caljon G., Natesan S. K., Saerens D., Conrath K., Pérez-Morga D., Skepper J. N., Nikolaou A., Brys L., Pays E., Magez S., Field M. C., De Baetselier P., Muyldermans S.: High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog., 2011;7:e1002072
75. Stijlemans B., Conrath K., Cortez-Retamozo V., Van Xong H., Wyns L., Senter P., Revets H., De Baetselier P., Muyldermans S., Magez S.: Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem., 2004;279:1256-1261
76. Stone E., Hirama T., Chen W., Soltyk A. L., Brunton J., MacKenzie C. R., Zhang J.: A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. Mol. Immunol., 2007, 44:2487-2491
77. Thomassen Y. E., Verkleij A. J., Boonstra J., Verrips C. T.: Specific production rate of VHH antibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation. J. Biotechnol., 2005;118:270-277
78. Ulrichts H., Silence K., Schoolmeester A., de Jaegere P., Rossenu S., Roodt J., Priem S., Lauwereys M., Casteels P., Van Bockstaele F., Verschueren K., Stanssens P., Baumeister J., Holz J. B.: Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 2011;118:757-765
79. Ungar-Waroni H., Elias E., Gluckman A., Trainin Z.: Dromedary IgG: purification, characterization and quantitation in sera of dams and newborns. Israel J. Vet. Med., 1987;43:198-203
80. van Loon J. E., de Jaegere P. P., Ulrichts H., van Vliet H. H., de Maat M. P., de Groot P. G., Simoons M. L., Leebeek F. W.: The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb. Haemost., 2011;106:165-171
81. Vandenbroucke K., de Haard H., Beirnaert E., Dreier T., Lauwereys M., Huyck L., Van Huysse J., Demetter P., Steidler L., Remaut E., Cuvelier C., Rottiers P.: Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol., 2010;3:49-56
82. Vu K. B., Ghahroudi M. A., Wyns L., Muyldermans S.: Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol. Immunol., 1997;34:1121-1131
83. Wahner-Roedler D. L., Kyle R. A.: Heavy chain diseases. Best Pract. Res. Clin. Haematol., 2005;18:729-746
84. Wei G., Meng W., Guo H., Pan W., Liu J., Peng T., Chen L., Chen C. Y.: Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One, 2011;6:e28309
85. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., Cauerhff A., Danquah W., Rissiek B., Scheuplein F., Schwarz N., Adriouch S., Boyer O., Seman M., Licea A., Serreze D. V., Goldbaum F. A., Haag F., Koch-Nolte F.: Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol., 2009;198:157-174
86. Woolven B. P., Frenken L. G., van der Logt P., Nicholls P. J.: The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics, 1999;50:98-101
87. Wörn A., Plückthun A.: Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry, 1999;38:8739-8750
88. Wu T. T., Johnson G., Kabat E. A.: Length distribution of CDRH3 in antibodies. Proteins, 1993;16:1-7
89. Zhang J., Li Q., Nguyen T. D., Tremblay T. L., Stone E., To R., Kelly J., MacKenzie R. C.: A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J. Mol. Biol., 2004;341:161-169
90. Zhang J., Tanha J., Hirama T., Khieu N. H., To R., Tong-Sevinc H., Stone E., Brisson J. R., MacKenzie C. R.: Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J. Mol. Biol., 2004;335:49-56